X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (44) 44
index medicus (32) 32
humans (30) 30
aged (29) 29
female (29) 29
male (29) 29
middle aged (28) 28
adult (27) 27
chemotherapy (24) 24
cancer (18) 18
aged, 80 and over (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
medicine & public health (13) 13
colorectal cancer (12) 12
prognosis (12) 12
treatment outcome (12) 12
cisplatin (11) 11
colorectal neoplasms - pathology (11) 11
gastric cancer (11) 11
metastasis (11) 11
retrospective studies (11) 11
stomach neoplasms - drug therapy (11) 11
camptothecin - analogs & derivatives (10) 10
care and treatment (10) 10
fluorouracil (10) 10
camptothecin - administration & dosage (9) 9
colorectal neoplasms - drug therapy (9) 9
antineoplastic agents - therapeutic use (8) 8
cancer research (8) 8
carcinoma (8) 8
5-fluorouracil (7) 7
adenocarcinoma - drug therapy (7) 7
bevacizumab (7) 7
esophageal cancer (7) 7
fluorouracil - administration & dosage (7) 7
irinotecan (7) 7
neoplasm staging (7) 7
stomach neoplasms - pathology (7) 7
surgical oncology (7) 7
tumors (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
disease-free survival (6) 6
gastroenterology (6) 6
kaplan-meier estimate (6) 6
leucovorin - administration & dosage (6) 6
metastases (6) 6
neoplasm metastasis (6) 6
squamous cell carcinoma (6) 6
stomach cancer (6) 6
survival (6) 6
survival rate (6) 6
trial (6) 6
analysis (5) 5
colorectal neoplasms - mortality (5) 5
gastroenterology & hepatology (5) 5
kras (5) 5
leucovorin (5) 5
medical prognosis (5) 5
paclitaxel (5) 5
patients (5) 5
pharmacology & pharmacy (5) 5
therapy (5) 5
adenocarcinoma - metabolism (4) 4
adenocarcinoma - mortality (4) 4
adenocarcinoma - secondary (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
biomarkers, tumor - blood (4) 4
cisplatin - administration & dosage (4) 4
colorectal neoplasms - genetics (4) 4
colorectal neoplasms - metabolism (4) 4
development and progression (4) 4
disease progression (4) 4
docetaxel (4) 4
drug combinations (4) 4
japan (4) 4
liver neoplasms - drug therapy (4) 4
liver neoplasms - metabolism (4) 4
liver neoplasms - secondary (4) 4
peritoneal neoplasms - drug therapy (4) 4
pharmacology/toxicology (4) 4
phase-ii (4) 4
prognostic factor (4) 4
adhesive processes not provided for elsewhere (3) 3
adhesives (3) 3
angiogenesis (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - adverse effects (3) 3
breast-cancer (3) 3
cancer therapies (3) 3
carcinoma, neuroendocrine - drug therapy (3) 3
carcinoma, neuroendocrine - mortality (3) 3
cetuximab (3) 3
chemistry (3) 3
chemoradiotherapy (3) 3
class i phosphatidylinositol 3-kinases (3) 3
colorectal carcinoma (3) 3
complications and side effects (3) 3
disease control (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastric Cancer, ISSN 1436-3291, 7/2017, Volume 20, Issue 4, pp. 655 - 662
Journal Article
Cancer Science, ISSN 1347-9032, 08/2014, Volume 105, Issue 8, pp. 1002 - 1007
c‐ MET is implicated in the pathogenesis and growth of a wide variety of human malignancies, including colorectal cancer ( CRC ). The aim of the present study... 
expression | hepatic metastasectomy | MET | Colorectal cancer | genetic mutational status | relapse‐free survival | Genetic mutational status | Hepatic metastasectomy | C-MET expression | Relapse-free survival | PRIMARY TUMORS | PIK3CA MUTATIONS | TYROSINE KINASE | KRAS STATUS | RECEPTOR | BRAF | relapse-free survival | BREAST-CANCER | CETUXIMAB | THERAPY | ONCOLOGY | CORRESPONDING METASTASES | c-MET expression | Immunohistochemistry | ras Proteins - genetics | Proto-Oncogene Proteins c-met - biosynthesis | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Hepatectomy | Young Adult | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Liver Neoplasms - secondary | Colorectal Neoplasms - metabolism | Neoplasm Recurrence, Local - metabolism | Biomarkers, Tumor - analysis | Kaplan-Meier Estimate | Proportional Hazards Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Class I Phosphatidylinositol 3-Kinases | Proto-Oncogene Proteins B-raf - genetics | Liver Neoplasms - metabolism | Neoplasm Recurrence, Local - genetics | Aged | Colorectal Neoplasms - pathology | Genetic research | Care and treatment | Genetic aspects | Surgery | Liver | Laboratories | Colorectal carcinoma | Metastasis | Family medical history | Kinases | Cancer therapies | Metastases | Proteins | Liver cancer | Ultrasonic imaging | Tomography | Growth factors | Antigens | Survival | Patients | Abdomen | Studies | Gene amplification | Medical prognosis | Protein expression | Mutation | Tumors | Index Medicus | Original
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 06/2019, Volume 37, Issue 3, pp. 573 - 578
Neuroendocrine tumors (NET) are rare tumors for which somatostatin analogs (SSA) are used not only for symptom control due to a functioning tumor, but also for... 
Octoreotide | Foregut NET | Neuroendocrine tumor | Hindgut NET | Lanreotide | Somatostatin analog | Complications and side effects | Dosage and administration | Effectiveness | Hindgut | Midgut | Liver | Medical treatment | Medical services | Disease control | Survival | Patients | Subgroups | Metastases | Analogs | Studies | Somatostatin | Foregut | Tumors | Neuroendocrine tumors
Journal Article
Cancer Science, ISSN 1347-9032, 05/2015, Volume 106, Issue 5, pp. 604 - 610
Skin toxicity is a known clinical signature used to predict the prognosis of anti‐epidermal growth factor receptor ( EGFR ) antibody treatment in metastatic... 
ligands | KRAS | EGFR | Colorectal cancer | skin toxicity | Ligands | Skin toxicity | RASH | EPIREGULIN | FAMILY-MEMBERS | INDUCTION | HUMAN KERATINOCYTES | CHEMOTHERAPY | CETUXIMAB | AMPHIREGULIN | ONCOLOGY | RESISTANCE | EXPRESSION | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Amphiregulin | Epiregulin - blood | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Transforming Growth Factor alpha - blood | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | EGF Family of Proteins - blood | Cetuximab | Skin - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Receptor, Epidermal Growth Factor - immunology | Antibodies, Monoclonal, Humanized - therapeutic use | Membrane Proteins - genetics | Proto-Oncogene Proteins - genetics | Treatment Outcome | Insulin-Like Growth Factor I - analysis | Biomarkers, Pharmacological - blood | Phosphatidylinositol 3-Kinases - genetics | Class I Phosphatidylinositol 3-Kinases | Hepatocyte Growth Factor - blood | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Mutation | Colorectal Neoplasms - pathology | Skin - drug effects | Viral antibodies | Epidermal growth factor | Antibodies | Skin | Metastasis | Transforming growth factors | Prognosis | Laboratories | Toxicity | Colorectal carcinoma | Cancer therapies | Metastases | Cell adhesion & migration | Enzyme-linked immunosorbent assay | Deoxyribonucleic acid--DNA | Immunoglobulins | Cytokines | Epidermal growth factor receptors | Hepatocyte growth factor | Survival | Patients | Serum levels | Chemotherapy | Medical prognosis | Biomarkers | Genetic testing | Tumors | Index Medicus | Original
Journal Article
Journal Article
Anticancer research, ISSN 0250-7005, 07/2019, Volume 39, Issue 7, pp. 3931 - 3936
Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC).... 
MULTICENTER | FLUOROURACIL | CANCER | DOCETAXEL | TRIAL | SUPPORTIVE CARE | CISPLATIN | ONCOLOGY | RANDOMIZED PHASE-II | S-1 | monotherapy | JAPAN | SQUAMOUS-CELL CARCINOMA | salvage | Esophageal cancer | squamous cell carcinoma | Esophageal carcinoma | Squamous cell carcinoma | Effectiveness | 5-Fluorouracil | Metastasis | Dosage | Disease control | Survival | Esophagus | Metastases | Refractory materials | Chemotherapy | Salvage | Platinum | Index Medicus
Journal Article
Investigational new drugs, ISSN 0167-6997, 07/2019, pp. 1 - 8
Background Ramucirumab (RAM) plus solvent-based (sb)-paclitaxel (PTX) is the standard second-line chemotherapy for advanced gastric cancer (AGC). The subset... 
Nanoparticles | Studies | Chemotherapy | Paclitaxel | Metastasis | Safety | Survival | Stomach cancer | Gastric cancer | Peritoneum | Cancer | Metastases
Journal Article
International Journal of Cancer, ISSN 0020-7136, 05/2012, Volume 130, Issue 10, pp. 2359 - 2365
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 103 - 103
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 3538 - 3538
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 124 - 124
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 4049 - 4049
Journal Article